Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis-Reference-Cited by-同舟云学术

Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis

Published:2016-03-16 Issue:4 Volume:77 Page:865-873
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Shin Dong-Yeop,Kim Seok Jin,Yoon Dok Hyun,Park Yong,Kong Jee Hyun,Kim Jeong-A,Kim Byung-Su,Kim Hyo Jung,Won Jong-Ho,Park Sung-Kyu,Kim Won Seog

Funder

Research grant from Merck Sharp & Dohme Corp.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-016-3005-y.pdf

Reference47 articles.

1. Howard OM, Gribben JG, Neuberg DS, Grossbard M, Poor C, Janicek MJ, Shipp MA (2002) Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol Off J Am Soc Clin Oncol 20(5):1288–1294

2. Kang BW, Sohn SK, Moon JH, Chae YS, Kim JG, Lee SJ, Kim WS, Lee JJ, Lee SR, Park KU, Lee HS, Lee WS, Won JH, Park MR, Kwak JY, Kim MK, Kim HJ, Oh SY, Kang HJ, Suh C (2014) Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: study by the Consortium for Improving Survival of Lymphoma. Blood Res 49(1):15–21

3. Schulz H, Bohlius JF, Trelle S, Skoetz N, Reiser M, Kober T, Schwarzer G, Herold M, Dreyling M, Hallek M, Engert A (2007) Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 99(9):706–714

4. Dreyling M, Geisler C, Hermine O, Kluin-Nelemans HC, Le Gouill S, Rule S, Shpilberg O, Walewski J, Ladetto M, Group EGW (2014) Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii83–92

5. McKay P, Leach M, Jackson R, Cook G, Rule S (2012) Guidelines for the investigation and management of mantle cell lymphoma. Br J Haematol 159(4):405–426

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combating relapsed and refractory Mantle cell lymphoma with novel therapeutic armamentarium: Recent advances and clinical prospects;Critical Reviews in Oncology/Hematology;2023-10

2. The trading of space for time under weakly activated catalysis: expeditious synthesis of β-NH₂ alcohols via a direct ammonolysis of epoxides with ammonia;Green Chemistry;2023

3. Systematic Literature Review of Economic Evaluations, Costs/Resource Use, and Quality of Life in Patients with Mantle Cell Lymphoma;PharmacoEconomics - Open;2020-09-29

4. Epigenetic targeting in lymphoma;British Journal of Haematology;2020-07

5. HDAC inhibitors in cancer therapy;Histone Modifications in Therapy;2020